Osteoarthritis Pain

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Acadia Pharmaceuticals
1 program
1
ACP-044 Dose APhase 21 trial
Active Trials
NCT05008835Terminated61Est. Nov 2022
M&
Merck & Co.RAHWAY, NJ
1 program
1
Comparator: Iontophoresis and Laser Doppler with ATPPhase 11 trial
Active Trials
NCT00917696Completed44Est. Jun 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Acadia PharmaceuticalsACP-044 Dose A
Merck & Co.Comparator: Iontophoresis and Laser Doppler with ATP

Clinical Trials (2)

Total enrollment: 105 patients across 2 trials

Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee

Start: Jul 2021Est. completion: Nov 202261 patients
Phase 2Terminated
NCT00917696Merck & Co.Comparator: Iontophoresis and Laser Doppler with ATP

Study to Evaluate ATP-induced Pain and ATP-induced Dermal Vasodilation by Iontophoresis (0000-118)(COMPLETED)

Start: Oct 2009Est. completion: Jun 201144 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space